Company: BIAF
Filing Date: 2025-06-27
Form Type: POS AM
Source: 0001641172-25-016927
Chunk: 82

Company: bioAffinity Technologies, Inc.
Filing Date: 2025-06-27
Form: POS AM
Chunk 82
---
 Warrants in accordance with the terms thereof. Notwithstanding the foregoing, in the event of a Fundamental Transaction, the holders of the October 2024 Common Warrants have the right to require us or a successor entity to redeem the October 2024 Common Warrants for cash in the amount of the Black Scholes Value (as defined in the October 2024 Common Warrants) of the unexercised portion of the October 2024 Common Warrants concurrently with or within 30 days following the consummation of a Fundamental Transaction. However, in the event of a Fundamental Transaction which is not in our control, including a Fundamental Transaction not approved by our board of directors, the holders of the October 2024 Common Warrants will only be entitled to receive from us or our successor entity the same type or form of consideration (and in the same proportion), at the Black Scholes Value of the unexercised portion of the October 2024 Common Warrant that is being offered and paid to the holders of Common Stock in connection with the Fundamental Transaction, whether that consideration is in the form of cash, stock or any combination of cash and stock, or whether the holders of Common Stock are given the choice to receive alternative forms of consideration in connection with the Fundamental Transaction.

Except as otherwise provided in the October 2024 Common Warrants or by virtue of such holder’s ownership of shares of Common Stock, the holder of a October 2024 Common Warrant will not have the rights or privileges of a holder of Common Stock, including any voting rights, until the holder exercises such warrant.

The October 2024 PA Warrants have substantially the same terms as the October 2024 Common Warrants, including that they have an exercise price equal to $1.50 per share, except that they were immediately exercisable upon issuance and expire on the five-year anniversary of the date of issuance.

Support Agreements

Certain of our stockholders holding in excess of 16% of our outstanding shares of Common Stock have entered into a Support Agreement, pursuant to which such stockholders have agreed, at every meeting of the holders of our Common Stock that our stockholders are requested to vote upon a proposal to approve the exercise in full of the October 2024 Common Warrants and the issuance of the October 2024 Common Warrant Shares upon exercise of the October 2024 Common Warrants, to vote all of the shares of Common Stock that they own in favor the such proposal as well as any proposal to approve an adjournment